T cell bispecific antibody for the immune-mediated killing of HER2+ breast cancer cells

VIDEO: This is a Q&A Round with Joaquín Arribas, Director of Preclinical Research at VHIO and Irene Rius Ruiz, Graduate Student of VHIO’s Growth Factors Group. view more 

view more 

It is not so long ago that immunotherapy against cancer was positioned as emerging or even promising but not as proven. Novel immunotherapeutics across different tumor types, either as mono therapy or in combination, are increasingly becoming one of the most innovative and powerful anti-cancer strategies.

One of the major challenges in ensuring that these novel treatments realize their true potential has been successfully equipping the immune system to launch its attack exclusively on tumour cells excluding all healthy tissues. Up until now.

Research led by Joaquín Arribas, Director of Preclinical Research at the Vall d’Hebron Institute of Oncology (VHIO), ICREA Professor, and Scientific Director of the Center for the Biomedical Research Network in Oncology (CIBERONC), has turned this obstacle into therapeutic opportunity.

Published in Science Translational Medicine, the study, first co-authored by Irene Rius-Ruiz, Graduate Student of VHIO’s Growth Factors Group, reveals that p95HER2-T cell bispecific antibody (TCB) can successfully guide immune cells, known as lymphocytes, directly to cancerous ones for their targeted killing.

This direct delivery is achieved thanks to


Article originally posted at


Click here for the full story


Privacy Policy / Terms Of Use

       Powered by MMD